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Abstract
Objective To summarise the effects of anthelmintic
drug treatment on growth and cognitive performance
in children.
Data sources Electronic databases: Cochrane
Infectious Diseases Group controlled trial register,
Cochrane controlled trials register, Embase, and
Medline. Citations of all identified trials. Contact with
the World Health Organization and field researchers.
Review methods Systematic review of randomised
controlled trials in children aged 1›16 that compared
anthelmintic treatment with placebo or no treatment.
Assessment of validity and data abstraction conducted
independently by two reviewers.
Main outcome measures Growth and cognitive
performance.
Results Thirty randomised controlled trials in more
than 15 000 children were identified. Effects on mean
weight were unremarkable, and heterogeneity was
evident in the results. There were some positive effects
on mean weight change in the trials reporting this
outcome: after a single dose (any anthelmintic) the
pooled estimates were 0.24 kg (95% confidence
interval 0.15 kg to 0.32 kg; fixed effects model
assumed) and 0.38 kg (0.01 kg to 0.77 kg; random
effects model assumed). Results from trials of multiple
doses showed mean weight change in up to one year
of follow up of 0.10 kg (0.04 kg to 0.17 kg; fixed
effects) or 0.15 kg (0.00 to 0.30; random effects). At
more than one year of follow up, mean weight change
was 0.12 kg (-0.02 kg to 0.26 kg; fixed effects) and
0.43 (-0.61 to 1.47; random effects). Results from
studies of cognitive performance were inconclusive.
Conclusions There is some limited evidence that
routine treatment of children in areas where
helminths are common has effects on weight gain, but
this is not consistent between trials. There is
insufficient evidence as to whether this intervention
improves cognitive performance.
Introduction
One third of the world’s population is infected with
one or more species of intestinal helminth,1 and public
health specialists are concerned that these infections
impair children’s growth and development. Studies
have shown associations between helminth infection
and undernutrition, iron deficiency anaemia, stunted
growth, poor school attendance, and poor perform›
ance in cognition tests.2–5 Better sanitation reduces
transmission, but another approach is to treat children
or whole populations routinely to reduce infection
rates. Whether this is a sustainable solution is not clear,
as rapid reinfection occurs.6 Reports of successful com›
bined programmes spanning several decades have
come from Japan.7
The World Bank claims that worm infections
impair learning and that helminth control is one of the
most cost effective strategies to improve health in
developing countries.8 Both the World Bank and World
Health Organization (WHO) promote helminth
control programmes in developing countries as a cost
effective intervention.9 Programmes aim to “target
mass treatment of children,” giving all children in com›
munities where worms are endemic anthelmintic
drugs every three to six months. Treatment regimens
depend on local prevalence rates.6 8–12 Although studies
have shown that available drugs are effective in
decreasing parasite infection rates, it is not clear if these
approaches actually improve the growth and cognitive
performance of children.13 14 We summarised the avail›
able evidence from trials of effects of anthelmintic drug
programmes on growth and cognitive performance in
children.
Methods
Inclusion criteria
We included all randomised and quasirandomised
controlled trials in children aged 1›16 years, allocated
to either anthelmintic drug treatment for intestinal
nematodes with any anthelminth drug (mebendazole,
piperazine, albendazole, levamisole, pyrantel, thiaben›
dazole, bephenium, tetrachlorethylene, metronidazole,
and ivermectin) or placebo (or no treatment). We
required trials to report outcomes related to growth or
cognitive performance, and these were our primary
outcomes. We had no restrictions on language,
publication status, or where the intervention was
dispensed.
Identification of trials
We searched the controlled trial register of the
Cochrane Infectious Diseases Group, the Cochrane
controlled trials register, Embase, and Medline using
terms related to specific infections and specific
common drugs. WHO and field researchers were con›
tacted for unpublished or ongoing trials. Citations of
all trials identified in the search were checked for
further references.
Study selection and data extraction
Two reviewers independently carried out study
selection and assessment of study quality (RD and PW).
Data on growth outcomes were extracted independ›
ently by two reviewers using previously designed data
extraction tables (RD and SA). Data related to cognitive
performance were extracted by one reviewer (CD) and
checked by a second reviewer (RD). Assessment of trial
quality included evaluation of concealment of alloca›
tion, method of randomisation, method of analysis, and
loss to follow up.
The tables of
results are available
on the BMJ website
Papers
International
Health Division,
Liverpool School of
Tropical Medicine,
Liverpool L3 5QA
Rumona Dickson
lecturer
Paul Garner
senior lecturer
Department of
Paediatrics and
Epidemiology, King
George Medical
College, Lucknow,
India
Shally Awasthi
associate professor of
paediatrics
Department of
Mathematical
Sciences, University
of Liverpool,
Liverpool L69 3BX
Paula Williamson
lecturer
Department of
Clinical Psychology,
University of
Liverpool
Colin Demellweek
lecturer
Correspondence to:
R Dickson
rdickson@liv.ac.uk
BMJ 2000;320:1697–701
1697BMJ VOLUME 320 24 JUNE 2000 bmj.com
Statistical analysis
For each continuous outcome specified we calculated a
pooled estimate of the weighted mean difference
across the studies and applied a ÷2 test for homogenei›
ty. Analyses of results from single and multiple dose
trials in the short term (less than one year) and long
term (over one year) were undertaken separately.
Within these categories analysis was carried out to
compare each drug with placebo or no treatment
independently and overall. When there was significant
heterogeneity both fixed and random effects estimates
are given. We explored heterogeneity by type of drug,
age of children, and intensity of infection.
Description of studies
Thirty trials (reported in 36 reports) met the inclusion
criteria (details can be found on the BMJ website).13–47
Of these, five (reported in seven reports18 24 30 33 35–37)
reported cognitive outcomes, while two reports from
one study included both cognitive and growth
outcomes.45 46 Two trials that reported effects on
growth or nutrition compared the effectiveness of
different drug dosages or drugs and are not included in
this review.48 49 Twenty eight trials were published
reports, one was a report drafted in 1997 (S Awasthi,
unpublished data), and one was an unpublished report
of preliminary data from an ongoing trial.16 The results
of all included trials were available in English. The trials
were carried out in 17 countries in four continents
(Africa, Asia, Central America, and South America).
Drugs assessed in these trials included albendazole,
piperazine, mebendazole, levamisole, pyrantel, and
tetrachlorethylene. Follow up periods for single dose
trials were from four weeks to one year (15 trials) and
for multiple dose trials were from 26 weeks to six years
(15 trials).
Children included in the trials were recruited from
school populations in 17 trials, rural communities in
nine trials, and through health clinics or health
workers in four trials. Twenty seven of the included
trials used “targeted mass treatment”—that is, all
children were treated regardless of infection status.1
The other three trials used “targeted screening,” in
which children were screened and only infected
children were eligible for inclusion.
Overall quality of the trials was poor. Of the 30
included studies, only three adequately reported
concealed allocation, and 24 made no mention of con›
cealment of allocation. A further three trials men›
tioned that the list of participants was sorted according
to age, sex, or intensity of infection and then randomly
allocated to treatment or control groups. Four trials
specified the method of randomisation. Six trials used
cluster randomisation,16 21 24 34 42 44 but only two seem to
have adjusted for design effects in their analysis.16 42
Twenty eight trials seemed to use an intention to
treat analysis in so far as they reported children being
analysed in the groups to which they had been
randomised. One trial regrouped children after
randomisation according to the number of drug treat›
ments actually received.20 One trial excluded tall
children from their analysis as the results from these
children exceeded the upper limits of the comparison
reference values being used.32
Analysis of different outcomes and at different
times made a single estimate of loss to follow up prob›
lematic. As a general rule, loss to follow up was
calculated on the basis of measurements at the final
testing time. In five studies the degree of loss to follow
up was unclear.21 22 25 27 30 Eight studies had a loss to fol›
low up of less than 10%, while in 15 it was between 10%
and 35%. One study had loss to follow up of 40%,20
while a second failed to collect data on more than 60%
of study participants.44
Reporting of growth data varied. Some trials
reported actual weight or height at the end of follow
up, while others reported these variables as change in
weight or height, weight for height, or weight for age.
Some authors reported only a selected subset of the
data and data analysis.21 Selective reporting is a
concern in this review as it is unclear whether various
growth outcomes were analysed but only selected find›
ings reported.
One study acknowledged financial support for the
trial from a drug company. Four stated they received
the drugs used in the trial from the manufacturer.
Results
Growth
Eleven trials evaluated a single dose treatment and
reported growth outcomes; two studies reported
results from single and multiple drug doses (S Awasthi,
unpublished data).16 An additional four multiple dose
trials recorded data after their first treatment dose, and
these data were included in the single dose
analysis.19 22 40 45 A subsequent sensitivity analysis that
excluded data from these four multiple dose trials did
not show any change in effect trends. Follow up varied
from four weeks to one year.
Five single dose studies that included data on
growth did not provide the data in a manner that
allowed for them to be included in the meta›analysis.
Four of these showed no differences in growth
measures between groups,13 17 27 31 while one showed a
difference in favour of the treatment group.28 All of the
tables of results are on the BMJ’s website. In summary,
for single dose trials the pooled estimates of increase in
weight were 0.24 kg (95% confidence interval 0.15 kg
to 0.32 kg; fixed effects model) and 0.38 kg (0.01 kg to
0.77 kg; random effects model). For multiple dose trials
the figures were 0.10 kg (0.04 kg to 0.17 kg; fixed
effects) and 0.15 kg (0.00 to 0.30; random effects) for
up to one year of follow up and 0.12 kg (-0.02 kg to
0.26 kg; fixed effects) and 0.43 (-0.61 to 1.47; random
effects) for more than one year of follow up.
In studies that provided data that could be used in
the meta›analysis there were significant differences in
relation to mean changes in weight, height, mid›upper
arm circumference, triceps and subscapular skinfold
measures, and mean triceps and subscapular skinfold
measures.
Fourteen trials reported on the effectiveness of
multiple doses with outcomes measured at one year or
less. Seven trials provided data that could be used in
the meta›analysis. There were significant differences in
mean change in weight and in mid›upper arm circum›
ference, and mean and mean change in triceps and
subscapular skinfold measures. Seven of the 14 trials
did not provide data that could be used in the
meta›analysis. Of these, two trials of mebendazole
found no differences in the groups.14 34 Two studies that
Papers
1698 BMJ VOLUME 320 24 JUNE 2000 bmj.com
assessed levamisole reported increases in weight and
height44 47; however, the trial reported by Thein et al
had a loss to follow up of over 60%.44 One trial that
used pyrantel or albendazole found no differences but
was confounded by a drop in rates of parasitism in
control children.26 Fernando et al reported only
selected data, from which no conclusions could be
drawn.21 Evans et al did not carry out an intention to
treat analysis because of crossovers in the trial but
found that children who received treatment with
pyrantel had increases in growth measures and a
decrease in morbidity as measured by the development
of measles.20
Results from the combination of two trials that
lasted more than one year and used albendazole
showed no difference between treatment and placebo
groups for measures of mean weight, and the mean
weight change of 120 g was not significant (S Awasthi,
unpublished data).16
Cognitive performance
Five studies reported on the effects of treatment on
measures of cognitive ability. Two studies that used
albendazole attempted to assess the effects of
anthelmintic treatment on academic progress. Watkins
et al examined reading vocabulary and attendance
records of 228 students treated with albendazole or
placebo and found no difference in the groups at six
months.46 Simeon et al examined performance on
reading, spelling, and arithmetic tests, as well as school
attendance, in 407 students and found no difference
between treated and untreated children positive for tri›
churis.35 The loss of 35% of the school attendance
records makes the interpretation of the results related
to school performance difficult. This research was
reported in three separate papers. Two of these studies
examined the effects of anthelmintic treatment in
different subgroups of children by using overlapping
but differing batteries of tests of cognitive ability.36 37
Neither study found a significant effect of treatment.
Nokes et al found some beneficial effect on some
aspects of cognitive functioning.32 33 Simeon et al failed
to find this benefit, although multiple regression analy›
sis found that children with heavy infections showed
more improvement than those with lighter infections.35
Boivin and Giordani found that anthelmintic treat›
ment with levamisole combined with iron supplemen›
tation had beneficial effects on cognitive function, but
they could not separate the effects of the two
treatments.18 In one other study, in which mebendazole
was not effective in significantly decreasing helminth
prevalence, there were no consistent changes in cogni›
tive performance after treatment,30 but the authors
attributed the lack of effect to the failure of drug treat›
ment. They consequently attempted to replicate their
study by using treatment specific for helminth
infection. Unfortunately a natural disaster (flood)
precluded data collection in the second study.
Hadidjaja et al compared the use of mebendazole
alone or in combination with health education.24 Their
groups, however, were not comparable at inception,
and loss to follow up was over 30%, with losses in some
groups over 50%. All studies that examined effects of
treatment on cognitive performance also measured
growth factors such as height and weight. Only one
study, however, provided data in a form that could be
used in the meta›analysis.45 46
Discussion
The main question examined in this review was the
effect of anthelmintics on growth and cognitive
performance. Therefore we did not examine drug
effects on intermediate outcomes such as worm infec›
tion. Head to head comparisons of different drugs are
not included as these are not relevant until benefits in
placebo controlled comparisons have been shown. We
did not consider intermediate laboratory variables
such as haemoglobin concentration. In fact, of the trials
that met our inclusion criteria only three reported this
outcome in a manner that could be used in the
meta›analysis, and the evidence of an effect is limited.50
We intended to analyse effects by prespecified
factors that could influence these estimates, including
the presence of malnutrition, infection species, and
intensity of infection. We also intended to stratify our
analysis by age, as this will strongly influence the size of
many growth outcomes. The data available from
individual trials, however, were insufficient to allow
subgroup analysis or meta›regression by any of these
factors. Analysis of data from individual patients might
start to unravel these subgroup effects but would be a
large task.
Not unexpectedly, and probably related to the fac›
tors mentioned above, several meta›analyses showed
heterogeneity between the results from different trials.
We considered presenting only those results with no
heterogeneity. Most growth outcomes are correlated
within patients, however, so we judged that reporting
only those meta›analyses where heterogeneity was
absent would be a bias in itself. For this reason, we
present all meta›analyses, and, where there was signifi›
cant heterogeneity, we have provided analysis using
both fixed and random effects models. The wide confi›
dence intervals with random effects reflect the
heterogeneity in the available data. Full details of indi›
vidual trial data are available from the Cochrane
Library.50
The trials
The analysis highlighted several methodological issues
that should be examined in future trials. Firstly, trial
quality varied. Most trials were small, and few reported
that they concealed allocation.
Secondly, most researchers obtained multiple
growth measures, but their reporting of these was
inconsistent. Authors variously reported absolute
values, changes in values, indices of values (such as
weight for height, height for age), and comparison of
values with accepted international reference data.
Researchers did not indicate their a priori primary
outcome. We were therefore unable to assess whether
the data presented were the intended primary
outcomes or whether a number of growth outcomes
were measured with the authors reporting only on sig›
nificant results. This bias, termed selective reporting,
may be done unwittingly by researchers but is
potentially an important unresearched source of bias
in systematic reviews of published literature.
Thirdly, growth is an indirect measure of health
outcome, and only one study examined more direct
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measures such as illness or mortality. Evans et al
attempted to examine morbidity measures such as epi›
sodes of diarrhoea, respiratory infection, or measles.20
The results of their study indicated that there were
fewer episodes of measles in treated children.
Finally, policy makers assume that these interven›
tions improve school attendance, and we specifically
sought this outcome. Two studies measured this, and
neither found an effect. Other studies used cognitive
tests, but what these mean and how they relate to a
child’s wellbeing is not clear. Researchers used a wide
range of tests, which made direct comparison difficult.
Even when the same test was used, such as the digit
span (forwards) and verbal fluency test, the effects were
not consistent between studies. Again, the hypothesis
that routine anthelmintic treatment will benefit a
subgroup of the population could not be explored with
the data available to us. A further difficulty is that most
tests for cognitive performance have not been
validated outside Western countries.51 52
On the other hand, the real problems in
implementing these trials should not be underesti›
mated, and difficulties can result in contamination,
which mitigates against the detection of true effect dif›
ferences between groups. In the study by Evans et al, in
which fortnightly assessments were carried out, the
researchers found that a proportion ( > 30%) of
children in the placebo group had actually received
intermittent anthelmintic treatment.20 The reported
crossover rate in the Awasthi trial further indicates the
difficulty in maintaining treatment groups within a
study population (S Awasthi, unpublished data).
Policy implications
Our interpretation of these findings is that the
evidence of benefit for mass treatment of children
related to positive effects on growth and cognitive per›
formance is not convincing. In the light of these data,
we would be unwilling to recommend that countries or
regions invest in programmes that routinely treat chil›
dren with anthelmintic drugs to improve their growth
or cognitive performance.
Research implications
There is a need for good quality, properly concealed,
placebo controlled trials to investigate the impact on
these outcomes. It is inefficient, unjustified, and
irrelevant to carry out head to head comparisons of
different anthelmintic drugs. A large cluster, ran›
domised trial in India is currently examining mortality
as an outcome, and the results of this work will be an
important contribution. International coordination,
possibly through the WHO, is required to ensure that
future trials are similar in design and that researchers
agree in advance to pool individual patients’ data in a
meta›analysis and to explore hypotheses about
subgroup effects in relation to age, worm load, and
exposure to infection.
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A book that changed my practice
New insights into mental illness
It had all become depressingly familiar: the suicidal teenager with
relationship difficulties; a middle›aged office worker who had lost
the energy to keep going; a lonely pensioner with insomnia and
multiple functional complaints. The answer to all of these and
many more was: start an antidepressant, take a few moments to
hear their complaints, refer for some counselling. And yet many
times nothing really helped. Despite the much vaunted hype and
advertising of antidepressants, most GPs will know how little they
can do for the patients we see daily.1
But then a friend gave me The Awakening by F Zuendel.2 At first
glance, it seemed irrelevant: an account of a 19th century
German pastor by the name of Blumhardt, working in the Black
Forest. But I read on to find a surprising record of people with
mental and physical illness, on whom the medical establishment
had given up. They found complete remission of their disease—all
carefully documented. How could this be explained?
Blumhardt knew that most psychiatrists of his day—like
today—ignore the fact that people have an innate sense of right
and wrong, and that no amount of drugs or counselling could
relieve them from the sense of burden they felt over past wrong
doings. Medical treatment was unable to offer them what they
needed most: forgiveness. This was not a question of dramatic
emotional conversions, but simply a chance to share with a
confidante and feel forgiven.
Though this flies in the face of scientific theory, even the most
cynical will have to admit that we do not understand all there is to
know about mental illness, and the fact that the mind may be
influenced in ways other than through pharmacologically defined
pathways should come as no surprise. Blumhardt had a great
respect for the medical profession and believed that it was the
church which was failing: “Especially in the case of mental illness,
most pastors cut a pathetic figure alongside physicians.” He set
out to change this, with surprising results.
So how has my practice changed? After reading this book,
several of my patients have been able to speak openly to fellow
church members in a way that they had not done for many years.
The result has been that they have come off their antidepressants
and are leading happier and more fulfilled lives. I have not seen
miracle cures or anything spectacular; I haven’t just blindly
stopped all antidepressants. But this new line of approach in what
seemed to be a dead end street has been most welcome. This
book opened up new dimensions to me and brought help to
patients who previously seemed beyond help.
E J Ben›Eliezer GP locum, East Sussex
1 Venning G. Antidepressant drugs have been shown to be ineffective in mild
depression. BMJ 2000;320:311.
2 Zuendel F. The Awakening. Robertsbridge, UK: Plough Publishing House,1999.
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